CONVALESCENT PLASMA REGISTRY
COVID-19 Convalescent Plasma Registry
Prior diagnosis of COVID-19, documented by a laboratory test
Present negative results for COVID-19, either from nasal swabs or a molecular (RNA or nucleic acid) diagnostic blood test
Symptom-free for 14 days prior to donation
If female, either no history of pregnancy or negative for HLA (tissue typing) antibodies
New Research Opportunities
Volunteers are needed now to test an investigational vaccine for the prevention of Ebola and Marburg viruses. Volunteers must be aged 18-50 and in good health. This vaccine does not contain any viruses and cannot cause Ebola or Marburg viruses.
Type 2 Diabetes Mellitus
The aim of the study is to investigate the long-term impact on cardiovascular morbidity, mortality and renal function of treatment with linagliptin in a selected population of patients with T2DM and to compare outcomes against placebo, on a background of standard of care.
This study consists of two parts, Part I and Part II. The purpose of Part I of the study is to assess the efficacy and safety of MK-8931 compared with placebo administered for 78 weeks in the treatment of Alzheimer's Disease (AD). The primary study hypotheses for Part I are that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score and that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) score. The first approximately 400 participants entering Part I of the study are identified as the Safety Cohort. Participants who complete Part I of the study may choose to participate in Part II, which is a long term double-blind extension to assess efficacy and safety of MK-8931 administered for up to an additional 260 weeks.